A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Seagen Inc.
Bold Therapeutics, Inc.
J-Pharma Co., Ltd.
TransThera Sciences (Nanjing), Inc.
Jazz Pharmaceuticals
Merck Sharp & Dohme LLC
Lisata Therapeutics, Inc.